Acadian Asset Management LLC Acquires 84,371 Shares of BrainsWay Ltd. (NASDAQ:BWAY)

Acadian Asset Management LLC grew its holdings in shares of BrainsWay Ltd. (NASDAQ:BWAY) by 48.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 259,787 shares of the company’s stock after purchasing an additional 84,371 shares during the quarter. Acadian Asset Management LLC owned about 1.56% of BrainsWay worth $1,567,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of BWAY. Rhumbline Advisers raised its holdings in BrainsWay by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock worth $110,000 after acquiring an additional 1,695 shares during the period. Virtu Financial LLC acquired a new position in BrainsWay during the 1st quarter worth $60,000. Essex Investment Management Co. LLC lifted its position in BrainsWay by 37.5% during the 1st quarter. Essex Investment Management Co. LLC now owns 324,843 shares of the company’s stock worth $1,718,000 after acquiring an additional 88,593 shares during the last quarter. Quadrature Capital Ltd acquired a new position in BrainsWay during the 4th quarter worth $70,000. Finally, Tucker Asset Management LLC lifted its position in BrainsWay by 1,686.9% during the 4th quarter. Tucker Asset Management LLC now owns 5,450 shares of the company’s stock worth $35,000 after acquiring an additional 5,145 shares during the last quarter. Institutional investors own 30.11% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on BWAY. HC Wainwright boosted their target price on shares of BrainsWay from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Northland Securities boosted their target price on shares of BrainsWay from $9.00 to $11.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 7th.

BrainsWay Stock Performance

NASDAQ:BWAY opened at $8.22 on Friday. The firm’s 50-day moving average is $7.27 and its 200-day moving average is $6.28. BrainsWay Ltd. has a 52-week low of $3.09 and a 52-week high of $8.35. The company has a market cap of $136.99 million, a price-to-earnings ratio of -91.33 and a beta of 1.25.

BrainsWay (NASDAQ:BWAY) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.04 earnings per share (EPS) for the quarter. BrainsWay had a net margin of 1.67% and a return on equity of 1.45%. The company had revenue of $10.01 million for the quarter, compared to the consensus estimate of $9.40 million. During the same quarter in the previous year, the firm posted ($0.05) EPS. Equities analysts predict that BrainsWay Ltd. will post 0.06 EPS for the current year.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.